YK Bioventures is the life-sciences venture firm whose own profile identifies Think Bio, Vivere, Moonwalk and Tempo.
Recorded funding activity
Think develops small-molecule medicines. Moonwalk targets fat-tissue pathways, while Tempo develops regenerative scaffolds. These programs pursue distinct therapeutic mechanisms within the recorded activity.
Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.